Sanofi Pasteur

From Wikipedia, the free encyclopedia
Jump to: navigation, search
sanofi pasteur
Founded August 2004 by merger
Headquarters Lyon, France
Key people
David Loew Executive Vice President, Vaccines [1]
Revenue €4.74 billion (2015)
Number of employees
Parent Sanofi

Sanofi Pasteur is the vaccines division of the multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines.

Sanofi Pasteur is one of four global producers of the yellow fever vaccine.[2]


In 2004, Aventis merged with and into Sanofi. The new Sanofi-Aventis Group became the world's 3rd largest pharmaceutical company. Aventis Pasteur, the vaccine division[3] of Sanofi-Aventis Group, changed its name to Sanofi Pasteur.[4] In 2014, Sanofi Pasteur stopped producing its effective Fav-Afrique antivenom because competition from cheaper though less powerful competitors made it unprofitable.[5] Doctors Without Borders said that it would take two years to develop a similar antivenom, and that existing stocks will run out in June 2016.[5]

Key dates[edit]

  • 1897: Marcel Mérieux creates the Mérieux Biological Institute in Lyon. Richard Slee creates the Pocono Biological Laboratories, in Swiftwater, Pennsylvania in the U.S.[6]
  • 1914: John G. FitzGerald creates Connaught Laboratories,[7] part of the University of Toronto.
  • 1968: Rhône-Poulenc acquires 51% of the capital of the Institut Mérieux.
  • 1974: Pasteur Institute creates Pasteur Production, a subsidiary specializing in manufacturing vaccines.
  • 1978: Connaught Laboratories in Canada acquires the vaccine manufacturing facility (Merrell-National Laboratories) at Swiftwater, Pennsylvania, U.S.
  • 1985: Pasteur Production is acquired by the Mérieux Institute, and Pasteur Vaccins is created.
  • 1989: The Mérieux Institute acquires the Connaught Laboratories in Canada and its subsidiaries and becomes a world leader in human biology.
  • 1990: Creation of Pasteur Mérieux Serums & Vaccins.
  • 1994: Pasteur Mérieux Sérums & Vaccins becomes a wholly owned subsidiary of Rhône-Poulenc.
  • 1996: Pasteur Mérieux Connaught is the new name of Pasteur Mérieux Serums et Vaccins.
  • 1999: Rhône-Poulenc and Hoechst unite their Life Sciences activities in a single company, which takes on the name Aventis. Within this group, Pasteur Mérieux Connaught changes its name to Aventis Pasteur.
  • 2004: merger of Aventis with and into Sanofi. The new Sanofi-Aventis Group becomes the world's 3rd largest pharmaceutical company, behind Pfizer and GlaxoSmithKline. Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi Pasteur.
  • 2008: Sanofi Pasteur acquires Acambis plc, a biotech company.
  • 2009: Sanofi Pasteur acquires major stake in Hyderabad-based Shantha Biotechnics.[8]

Key facts & figures in 2012[edit]

Sanofi Pasteur


2012 BCG supply shortage[edit]

In the fall of 2011 the Sanofi Pasteur plant flooded causing problems with mold.[14] The facility, located in Toronto, Ontario, Canada, produced BCG vaccine products, made with the Glaxo 1077 strain,[15] such as a tuberculosis vaccine ImmuCYST, a BCG Immunotherapeutic -a bladder cancer drug. By April 2012 the FDA had found dozens of documented problems with sterility at the plant including mold, nesting birds and rusted electrical conduits.[14] The resulting closure of the plant for over two years resulting in shortages of bladder cancer and tuberculosis vaccines.[16] The Toronto Sanofi plant [17] On October 29, 2014 Health Canada gave the permission for Sanofi to resume production of BCG.[18]

External links[edit]


  1. ^
  2. ^ "Yellow plague". The Economist. ISSN 0013-0613. Retrieved 2016-05-19. 
  3. ^ "Sanofi Pasteur Vaccine Hub". Retrieved 1 March 2014. 
  4. ^ "sanofi-aventis : Sanofi Pasteur, the vaccine division of the Sanofi-aventis Group, changes its name to sanofi pasteur". Retrieved 2007-11-04. 
  5. ^ a b Associated Press (7 September 2015). "Snakebite anti-venom running out worldwide, MSF". CBC News. Retrieved 8 September 2015. 
  6. ^ "Why vaccinate?". Retrieved 1 March 2014. 
  7. ^ "Connaught and the Canadian Polio Vaccine Story +". CONNTACT, June 1996 (Vol. 9 No. 3) (Employee News of Connaught Laboratories Limited). Retrieved 11 December 2012. 
  8. ^
  9. ^
  10. ^
  11. ^
  12. ^ a b c d e f g h i j k l m n o p q r s t u v w "Sanofi Pasteur US Products". Retrieved 2007-12-04. 
  13. ^ Staff Writer (25 April 2011). "FDA Grants Licensure To Expand Indication For Sanofi Pasteur's Menactra". RTTNews. Retrieved 26 April 2011. 
  14. ^ a b "April 2012 Inspectional Observations (form 483)", U.S. Food and Drug Administration, Vaccines, Blood & Biologics, April 12, retrieved 29 January 2016  Check date values in: |date= (help)
  15. ^ Fine, P.E.M (2004). Issues relating to the use of BCG in immunization programmes: A discussion document, WHO/V&B/99.23 (PDF). Geneva: WHO. 
  16. ^ Palmer, Eric (10 September 2014), "Merck again shipping BCG cancer treatment but Sanofi still is not: Shortages of bladder cancer and tuberculosis treatment have persisted for two years", FiercePharma 
  17. ^ Palmer, Eric (12 July 2012), "Merck again shipping BCG cancer treatment but Sanofi still is not: Shortages of bladder cancer and tuberculosis treatment have persisted for two years", FiercePharma 
  18. ^ Palmer, Eric (31 March 2015), "Sanofi Canada vax plant again producing ImmuCyst bladder cancer drug", FiercePharma, retrieved 29 January 2016